Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced the presentation of new pre-clinical data from its hypercholesterolemia program, performed in collaboration with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE